Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non‐inferiority sequential trial emulation
Journal of Internal Medicine · 2026-05 · 299 (5) · 604-614
DOI: 10.1111/joim.70079 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Journal of Internal Medicine, online erschienen am 28.02.2026. Verfasst von Maxime Beydon und 31 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Interne, Centre de référence des maladies lysosomales, Filière maladies héréditaires du métabolisme, Hôpital Beaujon, AP-HP.Nord,…. Hauptthemen laut MEDLINE: Gaucher Disease, Enzyme Replacement Therapy, Glucosylceramidase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi and Takeda.
Abstract (Originalsprache)
Objective
To compare the efficacy and safety of extended interval (Q3–4W) enzyme replacement therapy (ERT) versus standard biweekly (Q2W) ERT in clinically stable type 1 Gaucher disease (GD) patients.
Methods
We emulated a target trial with a sequential trial design, using data from the French Gaucher Disease Registry. Eligible patients were treated for ≥2 years biweekly without clinical events. Every 3 months, switchers to Q3–4W were matched to Q2W patients by age, sex, referral center follow‐up, disease history (bone events, anemia, thrombocytopenia, splenectomy, and hepatosplenomegaly), and dose of ERT. The primary outcome was a composite of GD‐related events (bone events, anemia, and thrombocytopenia). A 10% non‐inferiority margin was prespecified. Secondary outcomes were biomarker changes and economic analyses.
Results
Among 280 eligible GD patients, 63 switched to Q3–4W and were matched to a total of 215 Q2W patients, followed for an average of 6.3 years. No significant difference in the risk of clinical events was observed between groups (hazard ratio: 0.98 [95% confidence intervals (CI): 0.54–1.51]). During follow‐up, absolute risk difference remained below the 10% non‐inferiority threshold at all timepoints. Biomarkers remained stable or slightly decreased in the Q3–4W group. The dosing interval extension led to an average reduction of 55 infusions per patient, corresponding to approximately €450,000 saved per patient over 6 years.
Conclusion
In stable GD1 patients, extending ERT administration to every 3–4 weeks was non‐inferior to the standard biweekly regimen, supporting personalized spacing strategies that may improve quality of life and reduce healthcare costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Médecine Interne, Centre de référence des maladies lysosomales, Filière maladies héréditaires du métabolisme, Hôpital Beaujon, AP-HP.Nord, Université Paris Cité, Paris, France.
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe PEPITES, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Sorbonne Université, Paris,…
- Service de Médecine Interne Générale, Hôpitaux Universitaires de Genève, Genève, Switzerland.
- Pôle Recherche & Innovation, CHU de Montpellier, Montpellier, France.
- Centre de Référence des Maladies Lysosomales, Hôpital Necker-Enfants Malades, Filière G2M, Assistance Publique-Hôpitaux de Paris, IHU Institut Imagine, Paris, France.
- Service de Médecine Interne, Hôpital La Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
ORCID-Profile: Maxime Beydon, Dalil Hamroun, Yann Nadjar, Fabrice Camou, Yann Nguyen
Förderung
- Sanofi and Takeda
Zitieren
APA
Beydon, M., Stirnemann, J., Yousfi, K., Zebiche, S., Hamroun, D., Brassier, A., Pichard, S., Swiader, L., de Villemeur, T. B., Héron, B., Dalbies, F., Cador, B., Guemann, A. S., Gaches, F., Hivert, B., Leguy-Seguin, V., Masseau, A., Pers, Y. M., Pettazzoni, M., …, & French Evaluation of Gaucher Disease Treatment Committee (2026). Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non‐inferiority sequential trial emulation. Journal of Internal Medicine, 299(5), 604-614. https://doi.org/10.1111/joim.70079
Vancouver
Beydon M, Stirnemann J, Yousfi K, Zebiche S, Hamroun D, Brassier A, et al. Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non‐inferiority sequential trial emulation. Journal of Internal Medicine. 2026;299(5):604-614. doi:10.1111/joim.70079
BibTeX
@article{Beydon2026,
author = {Beydon, Maxime and Stirnemann, Jérôme and Yousfi, Karima and Zebiche, Samira and Hamroun, Dalil and Brassier, Anaïs and Pichard, Samia and Swiader, Laure and de Villemeur, Thierry Billette and Héron, Bénédicte and Dalbies, Florence and Cador, Bérengère and Guemann, Anne-Sophie and Gaches, Francis and Hivert, Bénédicte and Leguy-Seguin, Vanessa and Masseau, Agathe and Pers, Yves-Marie and Pettazzoni, Magali and Bekri, Soumeya and Caillaud, Catherine and Guillou, Edouard Le and Szymanowski, Marie and Astudillo, Leonardo and Mauhin, Wladimir and Nadjar, Yann and Serratrice, Christine and Berger, Marc G and Camou, Fabrice and Belmatoug, Nadia and Nguyen, Yann and French Evaluation of Gaucher Disease Treatment Committee, French Evaluation of Gaucher Disease Treatment Committee},
title = {Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non‐inferiority sequential trial emulation},
journal = {Journal of Internal Medicine},
year = {2026},
volume = {299},
number = {5},
pages = {604--614},
doi = {10.1111/joim.70079}
}
EUVIMED